PHARMEXCIL Strengthens Gov Partnership to Drive India’s $30 Bn Pharma Export Momentum

The council said it remains optimistic about sustaining and surpassing current pharma export levels as global healthcare demand stabilises.

The Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) has strengthened its engagement with key government departments to support the next phase of India’s pharma export growth.

This comes as overseas shipments cross $30 Bn, and global demand for affordable, quality-assured medicines from India remains steady despite pricing pressures.

PHARMEXCIL has held a series of meetings with senior officials from the Department of Commerce and Industry, the Department of Pharmaceuticals and the Directorate General of Foreign Trade.

The meeting focused on aligning policies, easing trade processes, encouraging innovation and expanding the participation of micro, small and medium enterprises in pharma export activity.

India’s pharmaceutical exports have reached $30.47 billion in FY25, registering a 9.4 per cent year-on-year growth at a time when several global markets continue to face pricing and regulatory pressures.

The sector remains one of the strongest contributors to India’s export basket, ranking fourth among export promotion councils, and supplying medicines to more than 150 countries across regulated and emerging markets.

The council said it remains optimistic about sustaining and surpassing current pharma export levels as global healthcare demand stabilises.

A major area of focus during the government interactions has been the integration of pharmaceutical MSMEs into global supply chains.

In parallel discussions with the Department of Pharmaceuticals, PHARMEXCIL underlined the importance of India’s expanding domestic market, currently estimated at around USD 60 bn and projected to reach USD 130 bn by 2030.

Engagements with the DGFT focused on trade facilitation measures to improve ease of doing business for exporters and accelerate participation across the pharma export ecosystem.

Discussions with the Department of Pharmaceuticals also covered strengthening industry-academia collaboration across clinical research, biopharmaceuticals, vaccines and APIs, with an emphasis on innovation and skill development.

Stay tuned for more such updates on Digital Health News